2101700-15-4 (吡托布鲁替尼,Pirtobrutinib)

BTK inhibitor 16;JNA39I7ZVB;(S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide;1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-;Pirtobrutinib;LOXO-305;(S)-5-Amino-3-{4-[(5-fluoro-2-methoxy-benzoylamino)-methyl]-phenyl}-1-(2,2,2-trifluoro-1-methyl-ethyl)-1H-pyrazole-4-carboxylic acid amide;5-amino-3-(4-{[(5-fluoro-2-methoxyphenyl)formamido]methyl}phenyl)-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide;MS-28909;CHEMBL4650485;LY 3527727;Y7W;LY3527727;PIRTOBRUTINIB [INN];Pirtobrutinib (LOXO-305)?;1H-Pyrazole-4-carboxamide, 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1S)-2,2,2-trifluoro-1-methylethyl]-;2101700-15-4;BDBM50594747;5-Amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1S)-2,2,2-trifluoro-1-methylethyl]-1H-pyrazole-4-carboxamide;HY-131328;DB-397939;LOXO 305;SCHEMBL19014257;WHO 11681;LY-3527727;5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-((2S)-1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE;Pirtobrutinib [USAN];5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide;UNII-JNA39I7ZVB;BTK Inhibitor LOXO-305;BL180882;PIRTOBRUTINIB [WHO-DD];pirtobrutinibum;RXC-005;AT37544;FWZAWAUZXYCBKZ-NSHDSACASA-N;PIRTOBRUTINIB [JAN];LOXO305;MCL133;GTPL11628;JAYPIRCA;RXC005;CHEBI:229212;AKOS040755166;LOXO-305;LY 3527727; RXC-005;GLXC-25733;CS-0133286;EX-A5016;5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide;

MFCD34179491

FWZAWAUZXYCBKZ-NSHDSACASA-N

1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1

FC([C@H](C)N1C(=C(C(N)=O)C(C2C=CC(CNC(C3C=C(C=CC=3OC)F)=O)=CC=2)=N1)N)(F)F